179003-10-2

Basic information

• Product Name: 4-[3-(METHOXYCARBONYL)PHENYL]-1-PIPERAZINECARBOXYLIC ACID, 1,1-DIMETHYLETHYL ESTER
• Synonyms: 4-[3-(METHOXYCARBONYL)PHENYL]-1-PIPERAZINECARBOXYLIC ACID, 1,1-DIMETHYLETHYL ESTER;4-[3-(Methoxycarbonyl)phenyl]-1-piperazinecarboxylic acid;tert-butyl 4-(3-(methoxycarbonyl)phenyl)piperazine-1-carboxylate
• CAS NO: 179003-10-2
• Molecular Formula: C₁₇H₂₄N₂O₄
• Molecular Weight: 320.38
• Mol File: 179003-10-2.mol
• Article Data: 9

Chemical Properties

• Boiling Point: 451.7°Cat760mmHg
• Flash Point: 227°C
• Appearance: /
• Density: 1.153g/cm³
• Vapor Pressure: 2.38E-08mmHg at 25°C
• Refractive Index: 1.535
• CAS DataBase Reference: 4-[3-(METHOXYCARBONYL)PHENYL]-1-PIPERAZINECARBOXYLIC ACID, 1,1-DIMETHYLETHYL ESTER(CAS DataBase Reference)
• NIST Chemistry Reference: 4-[3-(METHOXYCARBONYL)PHENYL]-1-PIPERAZINECARBOXYLIC ACID, 1,1-DIMETHYLETHYL ESTER(179003-10-2)
• EPA Substance Registry System: 4-[3-(METHOXYCARBONYL)PHENYL]-1-PIPERAZINECARBOXYLIC ACID, 1,1-DIMETHYLETHYL ESTER(179003-10-2)

Safety Data

• Hazardous Substances Data: 179003-10-2(Hazardous Substances Data)

Usage

General Description

The chemical 4-[3-(methoxycarbonyl)phenyl]-1-piperazinecarboxylic acid, 1,1-dimethylethyl ester is a compound used in medicinal research and drug development. It belongs to the class of piperazinecarboxylic acid derivatives, which have been studied for their potential as central nervous system depressants and as potential treatments for anxiety and depression. The 1,1-dimethylethyl ester group also suggests that this compound may have potential as a prodrug, meaning it could be metabolized in the body to release the active form of the drug. This chemical is of interest for its potential pharmacological properties and may have applications in the development of new therapeutic agents.

InChI:InChI=1/C17H24N2O4/c1-17(2,3)23-16(21)19-10-8-18(9-11-19)14-7-5-6-13(12-14)15(20)22-4/h5-7,12H,8-11H2,1-4H3

Upstream product

• 618-89-3 methyl 3-bromobenzoate 
• 57260-71-6 1-t-Butoxycarbonylpiperazine 
• 24424-99-5 di-tert-butyl dicarbonate 
• 179003-08-8 3-piperazine-4-yl-benzoic acid methyl ester 
• 4518-10-9 Methyl 3-aminobenzoate 
• 446831-28-3 3-(piperazin-1-yl)benzoic acid 
• 618-91-7 methyl 3-iodo-benzoate 

Downstream Products

• 193818-13-2 4-(3-carboxy-phenyl)-piperazine-1-carboxylic acid tert-butyl ester 
• 1447332-02-6 3-{6-[3-(4-boc-piperazin-1-yl)benzoylamino]-1-oxo-1,3-dihydroisoindol-2-yl}propionic acid 
• 1447332-14-0 3-{6-[3-(4-boc-piperazin-1-yl)benzoylamino]-1-oxo-1,3-dihydroisoindol-2-yl}butyric acid 
• 1447330-37-1 3-[1-oxo-6-(3-piperazinium-1-yl-benzoylamino)-1,3-dihydroisoindol-2-yl]propionic acid trifluoroacetate 
• 1447330-50-8 3-[1-oxo-6-(3-piperazinium-4-yl-benzoylamino)-1,3-dihydroisoindol-2-yl]butyric acid chloride 
• 1447331-52-3 3-{6-[3-(4-boc-piperazin-1-yl)benzoylamino]-1-oxo-1,3-dihydroisoindol-2-yl}propionic acid methyl ester 
• 1447331-70-5 3-{6-[3-(4-boc-piperazin-1-yl)benzoylamino]-1-oxo-1,3-dihydroisoindol-2-yl}butyric acid methyl ester 
• 261925-88-6 tert-butyl 4-(3-(hydroxymethyl)phenyl)piperazine-1-carboxylate 
• 179003-08-8 3-piperazine-4-yl-benzoic acid methyl ester 

Relevant articles and documents

Identification of Transthyretin Tetramer Kinetic Stabilizers That Are Capable of Inhibiting the Retinol-Dependent Retinol Binding Protein 4-Transthyretin Interaction: Potential Novel Therapeutics for Macular Degeneration, Transthyretin Amyloidosis, and Th

Dissociation of transthyretin (TTR) tetramers may lead to misfolding and aggregation of proamyloidogenic monomers, which underlies TTR amyloidosis (ATTR) pathophysiology. ATTR is a progressive disease resulting from the deposition of toxic fibrils in tiss

ISOXAZOLE ANALOGS AS FXR AGONISTS AND METHODS OF USE THEREOF

The present invention provides compounds of Formula I, pharmaceutical compositions comprising these compounds and methods of using these compounds to prevent or treat FXR-mediated or TGR5-mediated diseases or conditions.

TRIAZOLOPYRIDINE INHIBITORS OF MYELOPEROXIDASE

The present invention provides compounds of Formula (I): wherein A is as defined in the specification, and compositions comprising any of such novel compounds. These compounds are myeloperoxidase (MPO) inhibitors and/or eosinophil peroxidase (EPX) inhibitors, which may be used as medicaments.